Regeneron Pharmaceuticals, Inc. (REGN)
Summary
REGN Chart
Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down
REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition.
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Ryan Crowe - SVP, IR Leonard Schleifer - Board Co-Chair, Co-Founder, President and CEO George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - EVP, Commercial Chris Fenimore - EVP and CFO Conference Call Participants Tyler Van Buren - TD Cowen Alexandria Hammond - Wolfe Research Chris Schott - JPMorgan Terence Flynn - Morgan Stanley Akash Tewari - Jefferies Carter Gould - Cantor William Pickering - Bernstein Evan Seigerman - BMO Capital Markets Salveen Richter - Goldman Sachs David Risinger - Leerink Partners Operator Welcome to the Regeneron Pharmaceuticals' First Quarter 2025 Earnings Conference Call. My name is Josh, and I will be your operator for today's call.
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Regeneron Pharmaceuticals, Inc. Dividends
Regeneron Pharmaceuticals, Inc. Earnings
| 30 Apr 2025 (1 Days) Date | | - Cons. EPS | - EPS |
| 31 Jan 2025 Date | | 11.38 Cons. EPS | 12.07 EPS |
| 31 Oct 2024 Date | | 11.69 Cons. EPS | 12.46 EPS |
| 1 Aug 2024 Date | | 10.61 Cons. EPS | 11.56 EPS |
| 2 May 2024 Date | | 10.09 Cons. EPS | 9.55 EPS |
| 30 Apr 2025 (1 Days) Date | | - Cons. EPS | - EPS |
| 31 Jan 2025 Date | | 11.38 Cons. EPS | 12.07 EPS |
| 31 Oct 2024 Date | | 11.69 Cons. EPS | 12.46 EPS |
| 1 Aug 2024 Date | | 10.61 Cons. EPS | 11.56 EPS |
| 2 May 2024 Date | | 10.09 Cons. EPS | 9.55 EPS |
Regeneron Pharmaceuticals, Inc. (REGN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Regeneron Pharmaceuticals, Inc. ever had a stock split?
Regeneron Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Leonard S. Schleifer M.D., Ph.D. CEO | NASDAQ (NGS) Exchange | US75886F1075 ISIN |
| US Country | 13,450 Employees | - Last Dividend | - Last Split | 2 Apr 1991 IPO Date |
Overview
Regeneron Pharmaceuticals, Inc. is a biotechnology firm that is renowned for its dedication to discovering, inventing, developing, manufacturing, and commercializing medicines to combat a variety of diseases globally. Since its inception in 1988, the company has been at the forefront of innovative treatments, striving to address the unmet medical needs of patients around the world. With its headquarters nested in Tarrytown, New York, Regeneron has made a significant impact in the pharmaceutical industry by delivering life-changing medicines to patients in need.
Products and Services
Regeneron Pharmaceuticals, Inc. offers a diverse portfolio of products aimed at treating a wide range of diseases, including but not limited to, eye diseases, allergies and inflammations, cardiovascular and metabolic conditions, infectious diseases, rare diseases, cancers, pain, and hematologic conditions.
- EYLEA Injection: Used for the treatment of wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity.
- Dupixent Injection: Offers relief for adults and children suffering from atopic dermatitis and asthma, targeting the underlying inflammation and immune system response.
- Libtayo Injection: Approved for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma, providing a much-needed option for patients with this serious skin cancer.
- Praluent Injection: Aimed at adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, this medication works by reducing LDL cholesterol levels.
- REGEN-COV: For patients with COVID-19, offering a treatment option to help reduce the severity of the disease and potential hospitalization.
- Kevzara Solution: Designed for adults with rheumatoid arthritis, Kevzara works by interfering with the inflammatory pathway to reduce symptoms and slow disease progression.
- Inmazeb Injection: The first FDA-approved treatment for infection caused by Zaire ebolavirus, offering hope to patients facing this deadly disease.
- ARCALYST Injection: Treats cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome, by targeting the body’s inflammatory response.
- ZALTRAP Injection: Used in combination with chemotherapy for the treatment of metastatic colorectal cancer, aiming to slow the spread of the disease.
In addition to these products, Regeneron is continuously working on developing new treatments for a variety of diseases, demonstrating their commitment to innovation and improving patient health worldwide.
Contact Information
